Division of Microbiology, SydPath, St. Vincent’s Hospital, Darlinghurst, Australia.
Antimicrob Agents Chemother. 2012 Jan;56(1):487-94. doi: 10.1128/AAC.05125-11. Epub 2011 Oct 24.
Dientamoeba fragilis is a commonly encountered trichomonad which has been implicated as a cause of gastrointestinal disease in humans. Despite the frequency of reports recording infections with this parasite, little research has been undertaken in terms of antimicrobial susceptibility. The aim of this study was to evaluate the susceptibility of D. fragilis to several commonly used antiparasitic agents: diloxanide furoate, furazolidone, iodoquinol, metronidazole, nitazoxanide, ornidazole, paromomycin, secnidazole, ronidazole, tetracycline, and tinidazole. Antibiotic susceptibility testing was performed on four clinical strains of D. fragilis, designated A, E, M, and V, respectively. Molecular testing followed, and all strains were determined to be genotype 1. The activities of antiprotozoal compounds at concentrations ranging from 2 μg/ml to 500 μg/ml were determined via cell counts of D. fragilis trophozoites grown in dixenic culture. Minimum lethal concentrations (MLCs) were as follows: ornidazole, 8 to 16 μg/ml; ronidazole, 8 to 16 μg/ml; tinidazole, 31 μg/ml; metronidazole, 31 μg/ml; secnidazole, 31 to 63 μg/ml; nitazoxanide, 63 μg/ml; tetracycline, 250 μg/ml; furazolidone, 250 to 500 μg/ml; iodoquinol, 500 μg/ml; paromomycin, 500 μg/ml; and diloxanide furoate, >500 μg/ml. This is the first study to report the profiles of susceptibility to a wide range of commonly used treatments for clinical isolates of D. fragilis. Our study indicated 5-nitroimidazole derivatives to be the most active compounds in vitro against D. fragilis.
脆弱双核阿米巴是一种常见的毛滴虫,已被认为是人类胃肠道疾病的病因之一。尽管有频繁的报告记录了这种寄生虫的感染,但在抗菌药物敏感性方面的研究却很少。本研究旨在评估脆弱双核阿米巴对几种常用抗寄生虫药物的敏感性:二硝羟甲唑、呋喃唑酮、碘氯羟喹、甲硝唑、硝唑尼特、奥硝唑、巴龙霉素、塞克硝唑、罗硝唑、四环素和替硝唑。对分别命名为 A、E、M 和 V 的四个临床脆弱双核阿米巴株进行了抗生素药敏试验。随后进行了分子检测,所有菌株均被确定为基因型 1。通过在双栖培养中生长的脆弱双核阿米巴滋养体的细胞计数,测定了浓度范围为 2μg/ml 至 500μg/ml 的抗原生动物化合物的活性。最低致死浓度(MLC)如下:奥硝唑,8 至 16μg/ml;罗硝唑,8 至 16μg/ml;替硝唑,31μg/ml;甲硝唑,31μg/ml;塞克硝唑,31 至 63μg/ml;硝唑尼特,63μg/ml;四环素,250μg/ml;呋喃唑酮,250 至 500μg/ml;碘氯羟喹,500μg/ml;巴龙霉素,500μg/ml;二硝羟甲唑,>500μg/ml。这是第一项报告广泛使用的治疗脆弱双核阿米巴临床分离株的药敏谱的研究。我们的研究表明,5-硝基咪唑衍生物是体外对脆弱双核阿米巴最有效的化合物。